公众号 / 文章消化、代谢与肾脏急症重症综合管理与镇静镇痛

大麻与大麻素的治疗应用:综述

Therapeutic Use of Cannabis and Cannabinoids: A Review.
PubMed 文献 · JAMA · 2026-01-01
一句话结论大麻素仅对HIV/AIDS相关厌食、化疗所致恶心呕吐及某些儿科癫痫综合征获FDA批准,多数其他适应症证据不足,且高 potency 大麻与精神病性症状、焦虑及心血管风险相关。

本综述总结了美国与加拿大大麻药用现状及大麻素的治疗证据。FDA批准的大麻素适应症包括HIV/AIDS相关厌食、化疗所致恶心呕吐和某些儿科癫痫综合征。Meta分析显示处方大麻素对恶心呕吐有小的显著改善(SMD -0.29),对HIV/AIDS患者体重增加有中等效应(SMD 0.57)。循证指南不推荐吸入或高 potency 大麻(≥10%或10 mg Δ9-THC)用于医疗目的。高 potency 较低 potency 大麻与精神病性症状(12.4% vs 7.1%)和广泛性焦虑障碍(19.1% vs 11.6%)风险增加相关。观察性研究显示29%的医用大麻使用者符合大麻使用障碍标准。每日吸入大麻较非每日使用与冠心病(2.0% vs 0.9%)、心肌梗死(1.7% vs 1.3%)和卒中(2.6% vs 1.0%)风险增加相关。随机临床试验证据不支持大麻或大麻素用于急性疼痛和失眠等多数被宣传的适应症。临床医生在考虑医用大麻素前应查阅相关法规、评估药物相互作用和禁忌症(如妊娠),并与患者讨论减害策略。

要点

  • FDA批准的大麻素适应症仅限HIV/AIDS相关厌食、化疗所致恶心呕吐和某些儿科癫痫综合征。
  • Meta分析显示处方大麻素(如屈大麻酚、大麻隆)较安慰剂或活性对照对恶心呕吐有小的显著改善(SMD -0.29,95%CI -0.39至-0.18)。
  • 循证指南不推荐吸入或高 potency 大麻(≥10%或10 mg Δ9-THC)用于医疗目的。
  • 高 potency 较低 potency 大麻与精神病性症状(12.4% vs 7.1%)和广泛性焦虑障碍(19.1% vs 11.6%)风险增加相关。
  • 每日吸入大麻较非每日使用与冠心病(2.0% vs 0.9%)、心肌梗死(1.7% vs 1.3%)和卒中(2.6% vs 1.0%)风险增加相关。

适用人群与场景

  • 考虑使用大麻或大麻素治疗的患者,包括HIV/AIDS相关厌食、化疗所致恶心呕吐及某些儿科癫痫综合征患者。
  • 评估时需注意禁忌症如妊娠,以及风险可能大于获益的情况如精神分裂症或缺血性心脏病。

处置流程与药物剂量

  • 临床医生在考虑大麻或大麻素医疗用途前应查阅适用的机构、州和国家法规。
  • 应评估药物相互作用。
  • 应评估禁忌症(如妊娠)或风险可能大于获益的情况(如精神分裂症或缺血性心脏病)。
  • 对于使用大麻或大麻素治疗疾病的患者,临床医生应讨论减害策略,包括避免与酒精或其他中枢神经系统抑制剂(如苯二氮䓬类)同时使用、使用最低有效剂量、避免驾驶或操作机械时使用。

研究设计与关键结果

  • 综述总结了FDA批准的大麻素适应症:HIV/AIDS相关厌食、化疗所致恶心呕吐和某些儿科癫痫综合征。
  • Meta分析显示处方大麻素(如屈大麻酚、大麻隆)较安慰剂或活性对照(如阿立必利、氯丙嗪)对恶心呕吐有小的显著改善(SMD -0.29,95%CI -0.39至-0.18)。
  • Meta分析显示大麻素较安慰剂对HIV/AIDS患者体重增加有中等效应(SMD 0.57,95%CI 0.22至0.92)。
  • 高 potency 大麻较低 potency 大麻与精神病性症状(12.4% vs 7.1%)和广泛性焦虑障碍(19.1% vs 11.6%)风险增加相关。
  • 观察性研究Meta分析显示29%的医用大麻使用者符合大麻使用障碍标准。
  • 每日吸入大麻较非每日使用与冠心病(2.0% vs 0.9%)、心肌梗死(1.7% vs 1.3%)和卒中(2.6% vs 1.0%)风险增加相关。
  • 随机临床试验证据不支持大麻或大麻素用于急性疼痛和失眠等多数被宣传的适应症。

证据类型、等级与局限

  • 证据类型:综述,汇总随机临床试验Meta分析、观察性研究Meta分析及循证指南。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 临床医生应基于证据权衡获益与风险,与患者进行知情讨论。
  • 对于考虑医用大麻素的患者,应查阅法规、评估药物相互作用和禁忌症。
  • 对于使用大麻或大麻素的患者,应讨论减害策略如避免与酒精或苯二氮䓬类同用、使用最低有效剂量、避免驾驶或操作机械。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Approximately 27% of adults in the US and Canada report having ever used cannabis for medical purposes. An estimated 10.5% of the US population reports using cannabidiol (CBD), a chemical compound extracted from cannabis that does not have psychoactive effects, for therapeutic purposes.

OBSERVATIONS: Conditions for which cannabinoids have approval from the US Food and Drug Administration include HIV/AIDS-related anorexia, chemotherapy-induced nausea and vomiting, and certain pediatric seizure disorders. A meta-analysis of randomized clinical trials reported a small but significant reduction in nausea and vomiting from various causes (eg, chemotherapy, cancer) when comparing prescribed cannabinoids (eg, dronabinol, nabilone) with placebo or active comparators (eg, alizapride, chlorpromazine; standardized mean difference [SMD], -0.29 [95% CI, -0.39 to -0.18]). A meta-analysis of randomized clinical trials among patients with HIV/AIDS reported that cannabinoids had a moderate effect on increasing body weight compared with placebo (SMD, 0.57 [95% CI, 0.22 to 0.92]). Evidence-based guidelines do not recommend the use of inhaled or high-potency cannabis (≥10% or 10 mg Δ9-tetrahydrocannabinol [Δ9-THC]) for medical purposes. High-potency cannabis compared with low-potency cannabis use is associated with increased risk of psychotic symptoms (12.4% vs 7.1%) and generalized anxiety disorder (19.1% vs 11.6%). A meta-analysis of observational studies reported that 29% of individuals who used cannabis for medical purposes met criteria for cannabis use disorder. Daily inhaled cannabis use compared with nondaily use was associated with an increased risk of coronary heart disease (2.0% vs 0.9%), myocardial infarction (1.7% vs 1.3%), and stroke (2.6% vs 1.0%). Evidence from randomized clinical trials does not support the use of cannabis or cannabinoids for most conditions for which it is promoted, such as acute pain and insomnia. Before considering cannabis or cannabinoids for medical use, clinicians should consult applicable institutional, state, and national regulations; evaluate for drug-drug interactions; and assess for contraindications (eg, pregnancy) or conditions in which risks likely outweigh benefits (eg, schizophrenia or ischemic heart disease). For patients using cannabis or cannabinoids for treatment of medical conditions, clinicians should discuss harm reduction strategies, including avoiding concurrent use with alcohol or other central nervous system depressants such as benzodiazepines, using the lowest effective dose, and avoiding use when driving or operating machinery.

CONCLUSIONS AND RELEVANCE: Evidence is insufficient for the use of cannabis or cannabinoids for most medical indications. Clear guidance from clinicians is essential to support safe, evidence-based decision-making. Clinicians should weigh benefits against risks when engaging patients in informed discussions about cannabis or cannabinoid use.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Hsu M, Shah A, Jordan A, et al. Therapeutic Use of Cannabis and Cannabinoids: A Review. JAMA. 2026. PMID: 41296368. doi:10.1001/jama.2025.19433

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。